<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139371</url>
  </required_header>
  <id_info>
    <org_study_id>2013-574</org_study_id>
    <nct_id>NCT02139371</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography</brief_title>
  <official_title>64Cu-DOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor) for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Man.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for
      PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential
      of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and
      less aggressive tumors. This is a first in human study to test the radiotracer in cancer
      patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging (1,3
      and 24 hours post injection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for
      PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential
      of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and
      less aggressive tumors. This is a first in human study to test the radiotracer in cancer
      patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging (1,3
      and 24 hours post injection). The primary end points are Biodistribution and dosimetry of
      64Cu-DOTA-AE105. In addition, the quantitative uptake of 64Cu-DOTA-AE105 in tumors and
      expression of uPAR in tumor tissue obtained by surgery or biopsies (either 14 days before
      (only biopsies) or after the PET scans) will be compared to validate the image-derived data
      on UPAR expression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution</measure>
    <time_frame>24 hours</time_frame>
    <description>The patients will be PET scanned 1, 3 and 24 hours post injection of the radiotracer 64Cu-DOTA-AE105. These different timepoints will be used for assessment of biodistribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry</measure>
    <time_frame>24 hours</time_frame>
    <description>The patients will be PET scanned 1, 3 and 24 hours post injection of the radiotracer 64Cu-DOTA-AE105. These different timepoints will be used for calculation of dosimetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of UPAR in tumor tissue</measure>
    <time_frame>24 hours</time_frame>
    <description>Tumor uptake of 64Cu-DOTA-AE105 will be compared with expression of uPAR (using immunohistochemistry and ELISA) in tumor tissue obtained from biopsies/or operative removal of the tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative uptake of UPAR in tumor tissue</measure>
    <time_frame>24 hours</time_frame>
    <description>The patients will be PET scanned 1, 3 and 24 hours post injection of the radiotracer 64Cu-DOTA-AE105. These different timepoints will be used for assessment of tumor uptake of 64Cu-DOTA-AE105 will be assessed by PET scans 1, 3 and 24 hours post injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Urinary Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>64Cu-DOTA-AE105 PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Injection of 64Cu-DOTA-AE105</intervention_name>
    <description>One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection</description>
    <arm_group_label>64Cu-DOTA-AE105 PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of cancer of prostate, breast or urinary bladder

          -  capable of understanding and giving full informed consent

        Exclusion Criteria:

          -  pregnancy

          -  lactation

          -  contraindication for the use of intravenous CT contrast-agencies

          -  claustrophobia

          -  other current/or former diagnosed cancers, except non melanoma skin cancer or
             carcinoma in situ cervicis uteri
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorthe Skovgaard, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Persson M, Madsen J, Østergaard S, Jensen MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med. 2012 Jan;53(1):138-45. doi: 10.2967/jnumed.110.083386.</citation>
    <PMID>22213823</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Dorthe Skovgaard</investigator_full_name>
    <investigator_title>MD, Phd</investigator_title>
  </responsible_party>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Uroplasminogen Plasminogen Activator Receptor</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Urinary bladder cancer</keyword>
  <keyword>Biodistribution</keyword>
  <keyword>Radiation exposure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

